GSK Plans To Stop Further Development Of Camlipixant In Refractory Chronic Cough As Camlipixant 25mg Twice Daily Failed To Meet Statistical Significance In CALM-1, CALM-2 Clinical Trials

Loading news article.

GSK Plans To Stop Further Development Of Camlipixant In Refractory Chronic Cough As Camlipixant 25mg Twice Daily Failed To Meet Statistical Significance In CALM-1, CALM-2 Clinical Trials | WAPE

GSK Plans To Stop Further Development Of Camlipixant In Refractory Chronic Cough As Camlipixant 25mg Twice Daily Failed To Meet Statistical Significance In CALM-1, CALM-2 Clinical Trials

Article summary

Related companies

Comments —